secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001104659-24-026302
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics CFO C. Evan Ballantyne resigns; Gianluca Fuggetta appointed Principal Financial Officer
--------------------------------------------------------------------------------

- CFO C. Evan Ballantyne resigns effective March 1, 2024, departing all positions.
- Gianluca Fuggetta, current Senior Director, appointed VP of Finance and Principal Financial Officer from March 1.
- Company has initiated a search to identify a new Chief Financial Officer.
- Fuggetta previously served as Assurance Manager at PwC; joined Gain in July 2022.
- No family relationships or arrangements exist in connection with his appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924026302/0001104659-24-026302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924026302/tm245020d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-026302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer